Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 7/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.48 |
| ▸ | THRA | P10827 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 4/20 | 0.47 |
| ▸ | YWHAH | Q04917 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001945 | 0.93 | PLA2G2A (0.60) | PLA2G2AS1PR3THRATHRBYWHAH | |
| SCHEMBL2000334 | 0.91 | FOLH1 (0.51) | PLA2G2AS1PR3THRATHRBYWHAH | |
| SCHEMBL2001710 | 0.91 | PLA2G2A (0.52) | PLA2G2AS1PR3THRATHRBFOLH1 | |
| SCHEMBL2005441 | 0.90 | PLA2G2A (0.52) | PLA2G2AS1PR3THRATHRBYWHAH | |
| SCHEMBL2007112 | 0.85 | FOLH1 (0.51) | PLA2G2AS1PR3THRATHRBFOLH1 | |
| SCHEMBL2003130 | 0.85 | PLA2G2A (0.71) | PLA2G2ATHRATHRBPLA2G1B | |
| SCHEMBL2001937 | 0.84 | PLA2G2A (0.60) | PLA2G2AS1PR3THRATHRBPLA2G1B | |
| SCHEMBL2003149 | 0.84 | S1PR3 (0.57) | PLA2G2AS1PR3YWHAH | |
| SCHEMBL2004847 | 0.83 | PLA2G2A (0.49) | PLA2G2AS1PR3THRATHRBYWHAH | |
| SCHEMBL2007907 | 0.83 | PLA2G2A (0.46) | PLA2G2AS1PR3THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | PLA2G2A 3285/4885S1PR3 1215/4885THRA 1983/4885 |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | FAAH, FAAH2, AANAT | PLA2G2A 326/4885S1PR3 2165/4885THRA 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.